AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Valuation Inputs by Year
Valuation Inputs — Payment Probability Weighted Average (%) (%)
AbbVie Valuation Inputs: 100.0% in FY2025, unchanged from a year earlier.
Latest, FY2025
100.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
100.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Valuation Inputs — Payment Probability Weighted Average (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | 0.0 pts | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 100.0% | +1.0 pts | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 99.0% | 0.0 pts | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 99.0% | +3.0 pts | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 96.0% | +5.0 pts | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 91.0% | – | Form 10-K (filed 2022-02-18) ↗ |
Cite this data
StockData. (2026). AbbVie Valuation Inputs (%), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-prob-wavg
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.